Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13909250 | 1.00 | AR (0.48) | ARALDH1A1KDM4EMAPTUSP2 | |
| SCHEMBL4168220 | 0.90 | AR (0.50) | ARKDM4EMAPTLMNAGAA | |
| SCHEMBL13909246 | 0.90 | AR (0.50) | ARKDM4EMAPTLMNAGAA | |
| SCHEMBL4184243 | 0.90 | AR (0.45) | ARKDM4EMAPTLMNAGAA | |
| SCHEMBL14144349 | 0.88 | AR (0.54) | ARALDH1A1LMNAGAA | |
| SCHEMBL4170436 | 0.88 | AR (0.54) | ARALDH1A1LMNAGAA | |
| SCHEMBL13909244 | 0.88 | AR (0.54) | ARALDH1A1LMNAGAA | |
| SCHEMBL4167637 | 0.88 | AR (0.48) | ARALDH1A1MAPTHIF1A | |
| Methoxymethane SCHEMBL4167633 | 0.88 | MRGPRX4 (0.51) | ARALDH1A1LMNAGAA | |
| SCHEMBL13909408 | 0.88 | AR (0.48) | ARALDH1A1MAPTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | AR 145/4885ALDH1A1 695/4885KDM4E 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.